Prevention and management of prosthetic joint infection in older adults

Drugs and Aging

Volumn 28, Issue 1, 2011, Pages 13-26

  Shuman, Emily K ^a   Malani, Preeti N ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Antibacterials, therapeutic use; Elderly; Infections, prevention; Orthopaedic surgery; Postoperative infections, prevention.

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFAZOLIN; CEFUROXIME; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; GLUCOSE; PLACEBO; SUXAMETHONIUM; TEICOPLANIN; VANCOMYCIN; WARFARIN;

ACUTE KIDNEY FAILURE; ANAEROBE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTHROPLASTY; BACTERIUM CULTURE; BONE RADIOGRAPHY; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE BLOOD LEVEL; DEBRIDEMENT; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FUNGUS; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HEARING LOSS; HUMAN; HYPOTENSION; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; KIDNEY FUNCTION; MEDLINE; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OBESITY; PATHOGENESIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTHESIS INFECTION; PROSTHETIC JOINT INFECTION; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SURGICAL INFECTION; THORAX PAIN; THROMBOCYTOPENIA;

AGED; ANTIBIOTIC PROPHYLAXIS; ARTHROPLASTY, REPLACEMENT; HUMANS; PERIOPERATIVE CARE; PREOPERATIVE CARE; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS;

EID: 78650659942     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11586530-000000000-00000     Document Type: Review

References (66)

1. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009; 37 (10): 783-805
2. Hellmann M, Mehta SD, Bishai DM, et al. The estimated magnitude and direct hospital costs of prosthetic joint infections in the United States, 1997 to 2004. J Arthroplasty 2010; 25 (5): 766-71
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351 (16): 1645-54
4. Del Pozo JL, Patel R. Clinical practice: infection associated with prosthetic joints. N Engl J Med 2009; 361 (8): 787-94
5. Dellinger EP, Ehrenkranz NJ, Jarvis WR. Surgical site infections. In: Jarvis WR, editor. Bennett and Brachmans hospital infections. 5th ed. Philadelphia (PA): Lippincott, Williams, and Wilkins, 2007: 583-98
6. Murdoch DR, Roberts SA, Fowler Jr VG, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001; 32 (4): 647-9
7. Maderazo EG, Judson S, Pasternak H. Late infections of total joint prostheses: a review and recommendations for prevention. Clin Orthop Relat Res 1988; (229): 131-42
8. del Pozo JL, Patel R. The challenge of treating biofilmassociated bacterial infections. Clin Pharmacol Ther 2007; 82 (2): 204-9
9. Marculescu CE, Cantey JR. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res 2008; 466 (6): 1397-404
10. Mohanty SS, Kay PR. Infection in total joint replacements. Why we screen MRSA when MRSE is the problem? J Bone Joint Surg Br 2004; 86 (2): 266-8
11. Kourbatova EV, Halvosa JS, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 2005; 33 (7): 385-91
12. Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27 (5): 1247-54
13. Anderson DJ, Chen LF, Schmader KE, et al. Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2008; 29 (9): 832-9
14. Shuman EK, Malani PN. Preventing surgical site infections in older adults: the need for a new approach. Aging Health 2008; 4 (6): 567-9
15. Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; (182): 117-26
16. Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007; 357 (7): 654-63
17. Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl. 1: S51-61
18. Darouiche RO, Wall Jr MJ, Itani KM, et al. Chlorhexidinealcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010; 362 (1): 18-26
19. Swenson BR, Hedrick TL, Metzger R, et al. Effects of preoperative skin preparation on postoperative wound infection rates: a prospective study of 3 skin preparation protocols. Infect Control Hosp Epidemiol 2009; 30 (10): 964-71
20. Zywiel MG, Daley JA, Delanois RE, et al. Advance preoperative chlorhexidine reduces the incidence of surgical site infections in knee arthroplasty. Int Orthop. Epub 2010 Jun 20
21. Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2007; (2): CD004985
22. Hill C, Flamant R, Mazas F, et al. Prophylactic cefazolin versus placebo in total hip replacement: report of a multicentre double-blind randomised trial. Lancet 1981; I (8224): 795-6
23. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38 (12): 1706-15
24. Mauerhan DR, Nelson CL, Smith DL, et al. Prophylaxis against infection in total joint arthroplasty: one day of cefuroxime compared with three days of cefazolin. J Bone Joint Surg Am 1994; 76 (1): 39-45
25. Leigh DA. Serum and bone concentrations of cefuroxime in patients undergoing knee arthroplasty. J Antimicrob Chemother 1986; 18 (5): 609-11
26. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32 (9): 1320-2
27. Tyllianakis ME, Karageorgos AC, Marangos MN, et al. Antibiotic prophylaxis in primary hip and knee arthroplasty comparison between cefuroxime and 2 specific antistaphylococcal agents. J Arthroplasty 2010; 25 (7): 1078-82
28. Periti P, Stringa G, Mini E. Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin Microbiol Infect Dis 1999; 18 (2): 113-9
29. Summersgill JT, Schupp LG, Raff MJ. Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone. Antimicrob Agents Chemother 1982; 21 (4): 601-3
30. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326 (5): 281-6
31. Bannister GC, Auchincloss JM, Johnson DP, et al. The timing of tourniquet application in relation to prophylactic antibiotic administration. J Bone Joint Surg Br 1988; 70 (2): 322-4
32. Harbarth S, Samore MH, Lichtenberg D, et al. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101 (25): 2916-21
33. Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989; 106 (4): 750-6
34. Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. JGerontol A Biol SciMed Sci 1998; 53 (1): M59-63
35. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70 (4): 298-304
36. Cober ED, Malani PN. Clostridium difficile infection in the oldest old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009; 57 (4): 659-62
37. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole, cefazolin, vancomycin. Ann Surg 1987; 206 (2): 155-61
38. Wallace MR, Mascola JR, Oldfield 3rd EC. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 1991; 164 (6): 1180-5
39. Ritter MA, Barzilauskas CD, Faris PM, et al. Vancomycin prophylaxis and elective total joint arthroplasty. Orthopedics 1989; 12 (10): 1333-6
40. Albrecht 2nd RF, Lanier WL. Potentiation of succinylcholine- induced phase II block by vancomycin. Anesth Analg 1993; 77 (6): 1300-2
41. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341 (22): 1645-51
42. Gabel A, Schymik G, Mehmel HC. Ventricular fibrillation due to long QT syndrome probably caused by clindamycin. Am J Cardiol 1999; 83 (5): 813-5
43. Al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. Can J Anaesth 1995; 42 (7): 614-7
44. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995; 31 (1): 13-24
45. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346 (24): 1871-7
46. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299 (10): 1149-57
47. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362 (1): 9-17
48. Snyder JW, Munier GK, Johnson CL. Comparison of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) PCR assay to culture by use of BBL CHROMagar MRSA for detection of MRSA in nasal surveillance cultures from intensive care unit patients. J Clin Microbiol 2010; 48 (4): 1305-9
49. Wilcox MH, Hall J, Pike H, et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect 2003; 54 (3): 196-201
50. Kim DH, Spencer M, Davidson SM, et al. Institutional prescreening for detection and eradication of methicillinresistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery. J Bone Joint Surg Am 2010; 92 (9): 1820-6
51. Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008; 29 (6): 510-6
52. Miller MA, Dascal A, Portnoy J, et al. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17 (12): 811-3
53. Batra R, Cooper BS,Whiteley C, et al. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit.Clin InfectDis 2010; 50 (2): 210-7
54. Okano M, Nomura M, Hata S, et al. Anaphylactic symptoms due to chlorhexidine gluconate. Arch Dermatol 1989; 125 (1): 50-2
55. Hanssen AD. Prophylactic use of antibiotic bone cement: an emerging standard - in opposition. J Arthroplasty 2004; 19 (4 Suppl. 1): 73-7
56. Chiu FY, Chen CM, Lin CF, et al. Cefuroxime-impregnated cement in primary total knee arthroplasty: a prospective, randomized study of three hundred and forty knees. J Bone Joint Surg Am 2002; 84-A (5): 759-62
57. McQueen MM, Hughes SP, May P, et al. Cefuroxime in total joint arthroplasty: intravenous or in bone cement. J Arthroplasty 1990; 5 (2): 169-72
58. Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics versus gentamicin bone cement in total hip arthroplasty: a ten-year survey of 1,688 hips. Clin Orthop Relat Res 1993; (292): 210-4
59. Espehaug B, Engesaeter LB, Vollset SE, et al. Antibiotic prophylaxis in total hip arthroplasty: review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg Br 1997; 79 (4): 590-5
60. Malchau H, Herberts P, Ahnfelt L. Prognosis of total hip replacement in Sweden: follow-up of 92,675 operations performed 1978-1990. Acta Orthop Scand 1993; 64 (5): 497-506
61. Dunbar MJ. Antibiotic bone cements: their use in routine primary total joint arthroplasty is justified. Orthopedics 2009; 32 (9): 660
62. American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003; 134 (7): 895-9
63. American Academy of Orthopedic Surgeons. Information statement: antibiotic prophylaxis for bacteremia in patients with joint replacements [online]. Available from URL: http://www.aaos.org/about/papers/advistmt/1033.asp [Accessed 2010 Apr 23]
64. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospitalbased prospective case-control study. Clin Infect Dis 2010; 50 (1): 8-16
65. Little JW, Jacobson JJ, Lockhart PB. The dental treatment of patients with joint replacements: a position paper from the American Academy of Oral Medicine. J Am Dent Assoc 2010; 141 (6): 667-71
66. DeFrances CJ, Lucas CA, Buie VC, et al. 2006 national hospital discharge survey. Natl Health Stat Report 2008; (5): 1-20